monoclonal antibody gd2 anti-idiotype vaccine
mAbexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2003 (NCT00045617)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Disialoganglioside GD2Immunity, passive
Disialoganglioside GD2 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- monoclonal antibody gd2 anti-idiotype vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00045617 | Phase 2 | Jan 1, 2003 | National Cancer Institute (NCI), Southwest Oncology Group, University of Cincinnati |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2003 |
| Southwest Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2003 |
| University of Cincinnati | Academic/Hospital | 1 | 0 | 1 | 2003 |
3 organizations
Page 1 / 1